Health Sciences Authority’s Post

𝐕𝐢𝐜𝐭𝐨𝐫𝐢𝐚 𝐢𝐬 𝐟𝐨𝐫𝐠𝐢𝐧𝐠 𝐝𝐞𝐞𝐩𝐞𝐫 𝐭𝐢𝐞𝐬 𝐰𝐢𝐭𝐡 𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚 𝐢𝐧 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬, 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐢𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐚𝐝𝐯𝐚𝐧𝐜𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧. Explore the latest industry insights, including the Korea Health Industry Development Institute (KHIDI) and mRNA Victoria's commitment to jointly explore mRNA-based research, development, investment, clinical trials and commercialisation opportunities.  Learn more here: https://lnkd.in/g5uGkaGa Carolina Modesto | Yoshiko Tanaka #KoreaVictoriaPartnership #LifeSciences

MRgRT continues to gain global interest with growing clinical evidence and innovation. At the 19th MR-Linac Consortium meeting in Singapore, these advancements were in full focus💡 https://elekta.smh.re/8CZ

MRgRT continues to gain global interest with growing clinical evidence and innovation. At the 19th MR-Linac Consortium meeting in Singapore, these advancements were in full focus💡 https://elekta.smh.re/8BI

MRgRT continues to gain global interest with growing clinical evidence and innovation. At the 19th MR-Linac Consortium meeting in Singapore, these advancements were in full focus💡 https://elekta.smh.re/8CF

The expansion of industry sponsored research (ISR) has not only provided access of developing innovative treatments to patients in Malaysia, but has also featured the amazing performance of Malaysian investigators in global studies. A deep dive into PubMed have shown over 150 ISR peer-reviewed publications were authored by clinical researchers from Malaysia since 2019, including multiple publications in The New England Journal of Medicine, Lancet and even JAMA! Our heartiest congratulations to these clinicians who have achieved tremendous recognition in the clinical research realm! #clinicalresearchmy #advancingclinicalresearch #askusaboutclinicalresearch

Shaping the Future of Clinical Research in Pakistan: Key Takeaways from the #RCCTSymposium I had the privilege of attending the Symposium on Randomized Controlled Clinical Trials (RCCT) in Pakistan, organized by the UNESCO Chair on Medicine and Bio-organic Natural Product Chemistry-ICCBS, in collaboration with the Pakistan Academy of Sciences. The event featured insightful presentations from renowned experts like Prof. #Dr.M.Raza (#UNESCO Chair & GM, CBSCR at ICCBS), Dr. Atta-ur Rahman (Patron-In-Chief), Dr. Zeeshan Nasir, Dr. Saif ur Rehman Khattak, Professor Khalid Khan, Dr. Obaidullah Malik, and Dr. Naghma Hashmi. They explored the current landscape of #ClinicalTrials in Pakistan, emphasizing the critical importance of #Bioethics, regulatory frameworks, and the integrity of #ClinicalResearch. Events like these are vital for advancing our understanding and setting the direction for the future of clinical research in Pakistan. The collaboration and knowledge shared among leading figures and institutions ensure that our clinical trials align with global #HealthcareInnovation standards. #AcademicResearch #UNESCO #ICBS #PakistanAcademyofSciences

On November 12, the RIGHT Foundation hosted its annual forum, titled “Driving Global Health R&D with an End-to-End Approach Toward Equitable Access to Essential Health Technologies.” The forum was a side event of the 2024 World Bio Summit, co-hosted by the Ministry of Health and Welfare (MOHW) and the World Health Organization. The event brought together key stakeholders in global health, including representatives from the Korean government MOHW, the Ministry of Science and ICT, and the Ministry of Foreign Affairs, leading companies such as Bioneer, EuBiologics, LG Chem, Noul, SK bioscience, Shin Poong Pharm. Co., Ltd., READDI and Biovac, as well as international funders and research organizations like the ADB, Unitaid, and the CEPI. The forum attracted a full house of over 150 participants, reflecting the global interest in advancing health R&D for equitable access. The program was structured into three sessions: - Korea's Efforts to Contribute to Regional and Global Health - International Partnerships for Health Equity - What Does It Take to Support R&D with an End-to-End Approach? Catch the highlights from this event by watching the video linked below. #RIGHT #Bioneer #EuBiologics #LG_Chem #Noul #SKbioscience #ShinPoongPharm #Biovac #ADB #Unitaid #CEPI #READDI

At a biohealth policy forum on the sidelines of the recent CPHI Korea exhibition in Seoul, experts discussed what challenges Korea is facing in its quest to build competitive, global-level biopharma clusters, including governance, discontinuity of and insufficient investment, as well as the need to attract foreign firms and capital, reports Pink Sheet (Citeline Regulatory). https://lnkd.in/gFPXTVTC

The Subgroup for the Identification of Emerging Health Technologies (SG EHT) and the Subgroup for Joint Scientific Consultations (SG JSC) of the HTA Coordination Group have initiated a survey to identify the demand and interest for a JSC in 2025. Apparently, or hopefully, while the Implementing Act is developed (expected “Q2-Q3”), the current restraints and limitations are (finally) taken seriously. 💡A reminder: As of today, the JSC as a combined advice approach for regulatory and HTA is supposed to be only allowed before the pivotal study is initiated, only allowed once, with slots prioritized and limited, and a justification demanded if advice given is not followed. On paper, this does not appear to be a mutually welcoming framework – and has for tactical reasons already “forced” manufacturers to go the “old ways” of early interaction. We are always happy to help you as well with your strategic planning and assessing of advice options. Please find the survey until 31 May here: https://lnkd.in/eneBKFYc #JSC #JointScientificConsultations #EUHTA #JCA

We are pleased to launch series of Whitepaper Presentation on ‘India as a Preferred Destination for the Execution of Clinical Trials’ Here’s the first presentation on The Global Clinical Challenges and Opportunities, where we talk about: 1.1 USA: The Benchmark for Advanced Trials 1.2 Europe: Established but Facing Saturation 1.3 China: Rapid Growth but Lingering Regulatory Challenges 1.4 South Korea: Technological Prowess with Limitations 1.5 India: The Rising Contender India remains an unexplored territory regarding clinical research. Although India accounts for only 4% of global clinical trials, the country holds immense potential. CBCC having its direct presence in the US and India, learn how we are helping pharma and biotech companies bring the treatment to market faster! Please take a few moments to share some information with us on bd@cbcc.global and we will be in touch shortly. CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Avanish Mishra, Ph.D. Sanjeev Ganatra Nikhil Gandhi Harakh Shah, PMP® Tapan Shah Kinnari Gandhi RQAP-GCP Dr. Praveen Choudhary Nikunj Patel Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Jay Vyas Udayan Vyas